1
|
Sarangi M, Padhi S, Rath G. Non-Invasive Delivery of Insulin for Breaching Hindrances against Diabetes. Crit Rev Ther Drug Carrier Syst 2024; 41:1-64. [PMID: 38608132 DOI: 10.1615/critrevtherdrugcarriersyst.2023048197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/14/2024]
Abstract
Insulin is recognized as a crucial weapon in managing diabetes. Subcutaneous (s.c.) injections are the traditional approach for insulin administration, which usually have many limitations. Numerous alternative (non-invasive) slants through different routes have been explored by the researchers for making needle-free delivery of insulin for attaining its augmented absorption as well as bioavailability. The current review delineating numerous pros and cons of several novel approaches of non-invasive insulin delivery by overcoming many of their hurdles. Primary information on the topic was gathered by searching scholarly articles from PubMed added with extraction of data from auxiliary manuscripts. Many approaches (discussed in the article) are meant for the delivery of a safe, effective, stable, and patient friendly administration of insulin via buccal, oral, inhalational, transdermal, intranasal, ocular, vaginal and rectal routes. Few of them have proven their clinical efficacy for maintaining the glycemic levels, whereas others are under the investigational pipe line. The developed products are comprising of many advanced micro/nano composite technologies and few of them might be entering into the market in near future, thereby garnishing the hopes of millions of diabetics who are under the network of s.c. insulin injections.
Collapse
Affiliation(s)
| | - Sasmita Padhi
- Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University, Malhaur Railway Station Road, Gomti Nagar, Lucknow, Uttar Pradesh, Pin-201313, India
| | - Goutam Rath
- Department of Pharmaceutics, School of Pharmaceutical Sciences, Siksha 'O' Anusandhan University, Bhubaneswar-751030, Odisha, India
| |
Collapse
|
2
|
Ali FR, Shoaib MH, Ali SA, Yousuf RI, Siddiqui F, Raja R, Jamal HS, Saleem MT, Ahmed K, Imtiaz MS, Ahmad M, Sarfaraz S, Ahmed FR. A nanoemulsion based transdermal delivery of insulin: Formulation development, optimization, in-vitro permeation across Strat-M® membrane and its pharmacokinetic/pharmacodynamic evaluation. J Drug Deliv Sci Technol 2022. [DOI: 10.1016/j.jddst.2022.103338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
3
|
Ahad A, Raish M, Bin Jardan YA, Al-Mohizea AM, Al-Jenoobi FI. Delivery of Insulin via Skin Route for the Management of Diabetes Mellitus: Approaches for Breaching the Obstacles. Pharmaceutics 2021; 13:pharmaceutics13010100. [PMID: 33466845 PMCID: PMC7830404 DOI: 10.3390/pharmaceutics13010100] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2020] [Revised: 12/22/2020] [Accepted: 12/27/2020] [Indexed: 12/14/2022] Open
Abstract
Insulin is used for the treatment of diabetes mellitus, which is characterized by hyperglycemia. Subcutaneous injections are the standard mode of delivery for insulin therapy; however, this procedure is very often invasive, which hinders patient compliance, particularly for individuals requiring insulin doses four times a day. Furthermore, cases have been reported of sudden hypoglycemia occurrences following multidose insulin injections. Such an invasive and intensive approach motivates the quest for alternative, more user-friendly insulin administration approaches. For example, transdermal delivery has numerous advantages, such as prolonged drug release, low variability in the drug plasma level, and improved patient compliance. In this paper, the authors summarize different approaches used in transdermal insulin delivery, including microneedles, chemical permeation enhancers, sonophoresis, patches, electroporation, iontophoresis, vesicular formulations, microemulsions, nanoparticles, and microdermabrasion. Transdermal systems for insulin delivery are still being widely researched. The conclusions presented in this paper are extracted from the literature, notably, that the transdermal route could effectively and reliably deliver insulin into the circulatory system. Consistent progress in this area will ensure that some of the aforementioned transdermal insulin delivery systems will be introduced in clinical practice and commercially available in the near future.
Collapse
|
4
|
Affiliation(s)
- Aung Than
- School of Chemical and Biomedical Engineering, Innovative Centre for Flexible DevicesNanyang Technological University Singapore
| | - Ping Zan
- School of Chemical and Biomedical Engineering, Innovative Centre for Flexible DevicesNanyang Technological University Singapore
| | - Peng Chen
- School of Chemical and Biomedical Engineering, Innovative Centre for Flexible DevicesNanyang Technological University Singapore
| |
Collapse
|
5
|
An Y, Park MJ, Lee J, Ko J, Kim S, Kang DH, Hwang NS. Recent Advances in the Transdermal Delivery of Protein Therapeutics with a Combinatorial System of Chemical Adjuvants and Physical Penetration Enhancements. ADVANCED THERAPEUTICS 2020. [DOI: 10.1002/adtp.201900116] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Affiliation(s)
- Young‐Hyeon An
- School of Chemical and Biological EngineeringInstitute of Chemical ProcessesSeoul National University Seoul 08826 Republic of Korea
| | - Mihn Jeong Park
- Interdisciplinary Program in BioengineeringSeoul National University Seoul 08826 Republic of Korea
| | - Joon Lee
- Interdisciplinary Program in BioengineeringSeoul National University Seoul 08826 Republic of Korea
| | - Junghyeon Ko
- School of Chemical and Biological EngineeringInstitute of Chemical ProcessesSeoul National University Seoul 08826 Republic of Korea
| | - Su‐Hwan Kim
- Interdisciplinary Program in BioengineeringSeoul National University Seoul 08826 Republic of Korea
| | - Dong Hyeon Kang
- Interdisciplinary Program in BioengineeringSeoul National University Seoul 08826 Republic of Korea
| | - Nathaniel S. Hwang
- School of Chemical and Biological EngineeringInstitute of Chemical ProcessesSeoul National University Seoul 08826 Republic of Korea
- Interdisciplinary Program in BioengineeringSeoul National University Seoul 08826 Republic of Korea
- BioMAX Institute, Institute of BioengineeringSeoul National University Seoul 08826 Republic of Korea
| |
Collapse
|
6
|
A nano-sized gel-in-oil suspension for transcutaneous protein delivery. Int J Pharm 2019; 567:118495. [DOI: 10.1016/j.ijpharm.2019.118495] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2019] [Revised: 06/20/2019] [Accepted: 07/01/2019] [Indexed: 12/31/2022]
|
7
|
Positive effect of alendronate on bone turnover in ovariectomised rats’ osteoporosis: comparison of transdermal lipid-based delivery with conventional oral administration. Drug Deliv Transl Res 2018; 8:1078-1089. [DOI: 10.1007/s13346-018-0558-9] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
8
|
Lenn JD, Neil J, Donahue C, Demock K, Tibbetts CV, Cote-Sierra J, Smith SH, Rubenstein D, Therrien JP, Pendergrast PS, Killough J, Brown MB, Williams AC. RNA Aptamer Delivery through Intact Human Skin. J Invest Dermatol 2018; 138:282-290. [PMID: 28942363 DOI: 10.1016/j.jid.2017.07.851] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2017] [Revised: 07/04/2017] [Accepted: 07/25/2017] [Indexed: 01/09/2023]
Abstract
It is generally recognized that only relatively small molecular weight (typically < ∼ 500 Da) drugs can effectively permeate through intact stratum corneum. Here, we challenge this orthodoxy using a 62-nucleotide (molecular weight = 20,395 Da) RNA-based aptamer, highly specific to the human IL-23 cytokine, with picomolar activity. Results demonstrate penetration of the aptamer into freshly excised human skin using two different fluorescent labels. A dual hybridization assay quantified aptamer from the epidermis and dermis, giving levels far exceeding the cellular half maximal inhibitory concentration values (>100,000-fold), and aptamer integrity was confirmed using an oligonucleotide precipitation assay. A T helper 17 response was stimulated in freshly excised human skin resulting in significantly upregulated IL-17f, and IL-22; topical application of the IL-23 aptamer decreased both IL-17f and IL-22 by approximately 45% but did not result in significant changes to IL-23 mRNA levels, confirming that the aptamer did not globally suppress mRNA levels. This study demonstrates that very-large-molecular-weight RNA aptamers can permeate across the intact human skin barrier to therapeutically relevant levels into both the epidermis and dermis and that the skin-penetrating aptamer retains its biologically active conformational structure capable of binding to endogenous IL-23.
Collapse
Affiliation(s)
- Jon D Lenn
- MedPharm, Research Triangle Park, North Carolina, USA.
| | - Jessica Neil
- MedPharm, Research Triangle Park, North Carolina, USA
| | - Christine Donahue
- GlaxoSmithKline, R&D Platform Technology & Science, Waltham, Massachusetts, USA
| | - Kellie Demock
- GlaxoSmithKline, R&D Platform Technology & Science, Waltham, Massachusetts, USA
| | | | | | - Susan H Smith
- GlaxoSmithKline, Center For Skin Biology, Research Triangle Park, North Carolina, USA
| | - David Rubenstein
- GlaxoSmithKline, Center For Skin Biology, Research Triangle Park, North Carolina, USA
| | | | | | | | | | | |
Collapse
|
9
|
Chaulagain B, Jain A, Tiwari A, Verma A, Jain SK. Passive delivery of protein drugs through transdermal route. ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY 2018; 46:472-487. [PMID: 29378433 DOI: 10.1080/21691401.2018.1430695] [Citation(s) in RCA: 41] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Skin is the largest external organ in the human body but its use for therapeutic purposes has been minimal. Stratum corneum residing on the uppermost layer of the skin provides a tough barrier to transport the drugs across the skin. Very small group of drugs sharing Lipinski properties, i.e. drugs having molecular weight not larger than 500 Da, having high lipophilicity and optimum polarity are fortunate enough to be used on skin therapeutics. But, at a time where modern therapeutics is slowly shifting from use of small molecular drugs towards the use of macromolecular therapeutic agents such as peptides, proteins and nucleotides in origin, skin therapeutics need to be evolved accordingly to cater the delivery of these agents. Physical technologies like iontophoresis, laser ablation, micro-needles and ultrasound, etc. have been introduced to enhance skin permeability. But their success is limited due to their complex working mechanisms and involvement of certain irreversible skin damage in some or other way. This review therefore explores the delivery strategies for transport of mainly peptide and protein drugs that do not involve any injuries (non-invasive) to the skin termed as passive delivery techniques. Chemical enhancers, nanocarriers, certain biological peptides and miscellaneous approaches like prodrugs are also thoroughly reviewed for their applications in protein delivery.
Collapse
Affiliation(s)
- Bivek Chaulagain
- a Department of Pharmaceutical Sciences, Pharmaceutics Research Projects Laboratory , Dr. Hari Singh Gour Central University , Sagar , India
| | - Ankit Jain
- b Institute of Pharmaceutical Research, GLA University , Mathura , India
| | - Ankita Tiwari
- a Department of Pharmaceutical Sciences, Pharmaceutics Research Projects Laboratory , Dr. Hari Singh Gour Central University , Sagar , India
| | - Amit Verma
- a Department of Pharmaceutical Sciences, Pharmaceutics Research Projects Laboratory , Dr. Hari Singh Gour Central University , Sagar , India
| | - Sanjay K Jain
- a Department of Pharmaceutical Sciences, Pharmaceutics Research Projects Laboratory , Dr. Hari Singh Gour Central University , Sagar , India
| |
Collapse
|
10
|
Abstract
Developing a transdermal drug delivery system is a challenging task considering the selective permeability of the skin and the physicochemical properties the drug must possess to permeate through the skin. Lipid-based drug delivery systems have contributed a great deal in this direction in the last few decades, and thereby have helped to expand the range of therapeutic molecules that can be delivered through the skin in a safe and effective manner. Additionally, vesicular delivery systems such as nanoparticles and emulsions have also played important roles in providing alternative novel approaches for drug delivery. In this article, we will discuss some of the current and future lipid-based systems for transdermal drug delivery along with the associated challenges.
Collapse
|
11
|
Miller JD. An evolutionary perspective on intestinal lymphatic fat absorption, the industrialization of food, and allergy. Ann Allergy Asthma Immunol 2015; 113:339-42. [PMID: 25256027 DOI: 10.1016/j.anai.2014.07.026] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2014] [Accepted: 07/25/2014] [Indexed: 11/15/2022]
Affiliation(s)
- Jeffrey D Miller
- Department of Pediatrics, New York Medical College, Valhalla, New York; Department of Pediatrics, Danbury Hospital, Danbury, Connecticut; Mission: Allergy Inc, Hawleyville, Connecticut.
| |
Collapse
|
12
|
Foldvari M, Rafiee A. Perspectives on Using Nanoscale Delivery Systems in Dermatological Treatment. CURRENT DERMATOLOGY REPORTS 2015. [DOI: 10.1007/s13671-014-0092-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
13
|
Kumar D, Ali J, Baboota S. Omega 3 fatty acid-enriched nanoemulsion of thiocolchicoside for transdermal delivery: formulation, characterization and absorption studies. Drug Deliv 2014; 23:591-600. [DOI: 10.3109/10717544.2014.916764] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Lopes LB. Overcoming the cutaneous barrier with microemulsions. Pharmaceutics 2014; 6:52-77. [PMID: 24590260 PMCID: PMC3978525 DOI: 10.3390/pharmaceutics6010052] [Citation(s) in RCA: 99] [Impact Index Per Article: 9.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2013] [Revised: 01/24/2014] [Accepted: 02/11/2014] [Indexed: 11/16/2022] Open
Abstract
Microemulsions are fluid and isotropic formulations that have been widely studied as delivery systems for a variety of routes, including the skin. In spite of what the name suggests, microemulsions are nanocarriers, and their use as topical delivery systems derives from their multiple advantages compared to other dermatological formulations, such as ease of preparation, thermodynamic stability and penetration-enhancing properties. Composition, charge and internal structure have been reported as determinant factors for the modulation of drug release and cutaneous and transdermal transport. This manuscript aims at reviewing how these and other characteristics affect delivery and make microemulsions appealing for topical and transdermal administration, as well as how they can be modulated during the formulation design to improve the potential and efficacy of the final system.
Collapse
Affiliation(s)
- Luciana B Lopes
- Institute of Biomedical Science, University of São Paulo, São Paulo 05508, SP, Brazil.
| |
Collapse
|
15
|
Mou Y, Jiang X, Du Y, Xue L. Intelligent bioengineering in vitiligo treatment: Transdermal protein transduction of melanocyte-lineage-specific genes. Med Hypotheses 2012; 79:786-9. [DOI: 10.1016/j.mehy.2012.08.030] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2012] [Revised: 08/18/2012] [Accepted: 08/25/2012] [Indexed: 11/16/2022]
|
16
|
Intestinal receptor targeting for peptide delivery: an expert's personal perspective on reasons for failure and new opportunities. Ther Deliv 2012; 2:1575-93. [PMID: 22833983 DOI: 10.4155/tde.11.129] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
The technology has been available more than 25 years that would enable the oral delivery of vaccines, proteins and peptides, thus avoiding the need for injection. To this day, injection is still the mode of delivery, yet not the main mode of choice. This review focuses on several of the potential modes for oral delivery of peptides, proteins and vaccines. Additionally, the review will provide the reader with an insight into the problems and potential solutions for several of these modes of oral delivery of peptides and proteins.
Collapse
|
17
|
Krol S, Ellis-Behnke R, Marchetti P. Nanomedicine for treatment of diabetes in an aging population: state-of-the-art and future developments. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2012; 8 Suppl 1:S69-76. [PMID: 22640905 DOI: 10.1016/j.nano.2012.05.005] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/03/2011] [Revised: 12/01/2011] [Accepted: 12/03/2011] [Indexed: 01/05/2023]
Abstract
Nowadays diabetes, especially type 2 diabetes (which is strongly related to the Western diet and life-style), has developed worldwide into an epidemic disease. Nanomedicine aims to provide novel tools for diagnosis, therapy and point-of-care management of patients. Several nanotechnological approaches were developed to improve life quality for patients with insulin-dependent diabetes. They facilitate blood glucose management by non-invasive glucose measurement as well as insulin administration mainly by delivering the fragile protein as protected and targeted formulation via nasal or oral route. In the present review the oral or nasal insulin delivery by polymeric nanoparticles is discussed with focus on physiological change either related to the disease, diabetes or age-related metabolic variations influencing insulin release and bioavailability. One critical point is that new generations of targeted nanoparticle based drugs are developed and optimized for certain metabolic conditions. These conditions may change with age or disease. The influence of age-related factors such as immaturity in very young age, metabolic and physiologic changes in old age or insufficient animal models are still under-investigated not only in nanomedicine but also generally in pharmacology. Summarizing it can be noted that the bioavailability of insulin administered via routes others than subcutaneously is comparably low (max. 60%). Moreover factors like changed gut permeability as described for diabetes type 1 or other metabolic peculiarities such as insulin resistance in case of type 2 diabetes also play a role in affecting the development of novel nanoparticulated drug preparations and can be responsible for unsuccessful translation of promising animal results into human therapy. In future insulin nanoparticle development for diabetes must consider not only requirements imposed by the drug but also metabolic changes inflicted by disease or by age. Moreover new approaches are required for prevention of the disease.
Collapse
Affiliation(s)
- Silke Krol
- Fondazione IRCCS Istituto Neurologico Carlo Besta, IFOM-IEO-Campus, via Adamello 16, 201394 Milan, Italy.
| | | | | |
Collapse
|
18
|
Krol S, Ellis-Behnke R, Marchetti P. Nanomedicine for treatment of diabetes in an aging population: state-of-the-art and future developments. Maturitas 2011; 73:61-7. [PMID: 22209199 DOI: 10.1016/j.maturitas.2011.12.004] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2011] [Revised: 12/01/2011] [Accepted: 12/03/2011] [Indexed: 01/08/2023]
Abstract
Nowadays diabetes, especially type 2 diabetes (which is strongly related to the Western diet and life-style), has developed worldwide into an epidemic disease. Nanomedicine aims to provide novel tools for diagnosis, therapy and point-of-care management of patients. Several nanotechnological approaches were developed to improve life quality for patients with insulin-dependent diabetes. They facilitate blood glucose management by non-invasive glucose measurement as well as insulin administration mainly by delivering the fragile protein as protected and targeted formulation via nasal or oral route. In the present review the oral or nasal insulin delivery by polymeric nanoparticles is discussed with focus on physiological change either related to the disease, diabetes or age-related metabolic variations influencing insulin release and bioavailability. One critical point is that new generations of targeted nanoparticle based drugs are developed and optimized for certain metabolic conditions. These conditions may change with age or disease. The influence of age-related factors such as immaturity in very young age, metabolic and physiologic changes in old age or insufficient animal models are still under-investigated not only in nanomedicine but also generally in pharmacology. Summarizing it can be noted that the bioavailability of insulin administered via routes others than subcutaneously is comparably low (max. 60%). Moreover factors like changed gut permeability as described for diabetes type 1 or other metabolic peculiarities such as insulin resistance in case of type 2 diabetes also play a role in affecting the development of novel nanoparticulated drug preparations and can be responsible for unsuccessful translation of promising animal results into human therapy. In future insulin nanoparticle development for diabetes must consider not only requirements imposed by the drug but also metabolic changes inflicted by disease or by age. Moreover new approaches are required for prevention of the disease.
Collapse
Affiliation(s)
- Silke Krol
- Fondazione IRCCS Istituto Neurologico Carlo Besta, IFOM-IEO-Campus, Milan, Italy.
| | | | | |
Collapse
|